Sharp Therapeutics Updates on '901 for Gaucher and GBA1 Parkinson's and Platform Programs
Rhea-AI Summary
Sharp Therapeutics (OTCQB: SHRXF) announced on April 10, 2026 that it will advance an alternative compound for its Gaucher and GBA1 Parkinson's programs after longer-term non-GLP testing revealed suboptimal dose proportionality for the prior '901-series candidate.
The company says backup compounds show superior physical and metabolic properties, enabling rapid elevation to candidate status while continuing advancement of Niemann Pick Type C and Progranulin platform programs.
Positive
- Decision to advance a replacement candidate for Gaucher/GBA1 Parkinson's
- Backup program produced multiple compounds with superior properties
- Continued progress on Niemann Pick Type C lead compounds
- Ongoing Progranulin modulation program for broad neurodegeneration applications
Negative
- Suboptimal dose proportionality observed with '901 in longer-term non-GLP studies
- Delay in advancing original '901-series candidate to clinical development
News Market Reaction – SHRXF
In the Jun 16 session, SHRXF declined 8.23%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that following longer-term non-GLP testing the company has decided to advance an alternative compound for its Gaucher and GBA1 Parkinson's programs. The company continues to advance all platform programs including programs for genetic and sporadic forms of neurodegeneration (Progranulin modulators), and a rare neurodegenerative lysosomal disease (Niemann Pick Type C).
"Sharp has a high standard for advancing any therapeutic candidate into clinical development and while the '901-series compounds continue to perform quite well, based on the suboptimal dose proportionality of '901 in longer-term non-GLP studies we have made the decision to evaluate replacement candidates. Since nominating '901 our team has maintained an active backup program which has produced multiple compounds with superior physical properties and metabolic behavior (key drivers of dose-proportionality). This provides an opportunity to quickly elevate one of these compounds to candidate status for the Gaucher and GBA1 Parkinson's programs." said Scott Sneddon, Ph.D., JD, Sharp's CEO.
Dr. Sneddon continued: "The Gaucher/PD program has yielded compounds that restore GBA1 function through a novel mechanism, with potent activity in patient cells and in-vivo, and good oral availability and CNS penetrance. Advancing a compound with superior pharmaceutical properties provides the opportunity to bring the highest quality compound into Phase I development and eventually to patients. We continue to believe that our unique approach to addressing serious disease caused by GBA1 deficiency (Gaucher and GBA1-Parkinson's) could result in significant therapeutic and commercial opportunities and we continue to emphasize moving this program forward."
In the Company's view, the greatest value in Sharp is the platform that produces the assets it takes forward to development. Therefore, Sharp continues to advance small molecule therapies for Nieman Pick Type C as well, having discovered small molecule lead compounds that directly lower accumulated cholesterol in cells from patients, which would provide a unique therapeutic opportunity in that growing market.
Sharp is also advancing it other platform project: its small molecule Progranulin modulation program for broad potential application to neurodegenerative disease, including genetic and sporadic forms of Frontotemporal Dementia, Alzheimer's and Parkinson's.
About Sharp Therapeutics Corp.
First-Choice Therapies for Genetic Diseases
Sharp Therapeutics is a preclinical-stage company developing first-choice small-molecule therapeutics for genetic diseases. The Company's small molecule discovery platform combines novel high throughput screening technologies, with compound libraries computational optimized based on the physics and biology of cellular trafficking defects and allosteric activation of proteins. The platform produces small molecule compounds that restore activity in mutated proteins giving the potential to treat genetic disorders with conventional pill-based medicines.
For additional information on Sharp, please visit: www.sharptx.com.
Sharp Therapeutics Corp.
Scott Sneddon, PhD, JD
CEO/CSO
Email: scott@sharptx.com
Phone: (412) 206-5303
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect Sharp's current views and intentions with respect to future events, and current information available to Sharp, and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Should any factor affect Sharp in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Sharp does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release and Sharp undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/292009